For the full year 2025, selling general and administrative expenses of $35.2 million decreased compared to the prior year by $20.6 million, excluding the impact of stock-based compensation, driven primarily by the implementation of our more focused commercial strategy for YCAMP, including decreases in compensation benefits and travel due to the reduced sales force of $6.9 million, decreased commercial costs of $6.6 million, decreased compensation of $2.7 million related to the termination of non-sales employees, decreased travel and fleet costs of $2 million, and decreased legal and administrative costs of $2.3 million.

Mar 11, 2026 / receipt, needs a key / John Kirby, CFO | earnings call 2026-03-11 | transcript 852b9610-2e16-4fbd-8f31-e63b4f859de9 | chars 18524-19151 | segment 18

For the full year 2024, selling general and administrative expenses were $58.8 million, compared to $47.3 million for the year ended December 31, 2023. The increase of $11.5 million was primarily a result of higher expenses related to commercial activities for WICAN for the treatment of molluscum, including increased compensation, recruiting fees, benefits and travel due to ramp-up of sales force of $8.5 million, as well as increased commercial-related costs of $5.1 million.

Mar 11, 2025 / receipt, needs a key / John Kirby, Interim CFO | earnings call 2025-03-11 | transcript 994a2fa7-639a-4e7c-aa46-9592d6a60b39 | chars 15857-16336 | segment 15